Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Thrombopoietin receptor agonist ==Preliminary data== <span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; ...") |
m (→Also known as) |
||
| (17 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
Thrombopoietin receptor agonist | Thrombopoietin receptor agonist | ||
| − | == | + | ==Diseases for which it is established== |
| − | + | *[[Immune thrombocytopenia]] | |
| − | + | *[[Thrombocytopenia in liver disease]] | |
| − | + | ||
| − | + | ==History of changes in FDA indication== | |
| − | + | * 2018-05-21: Approved for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] scheduled to undergo a procedure. | |
| − | + | ==History of changes in EMA indication== | |
| − | + | *2019-06-20: Initial authorization as Doptelet | |
| + | *Uncertain date: Doptelet is indicated for the treatment of severe [[Thrombocytopenia in liver disease|thrombocytopenia in adult patients with chronic liver disease]] who are scheduled to undergo an invasive procedure. | ||
| + | *Uncertain date: Doptelet is indicated for the treatment of primary chronic [[Immune thrombocytopenia|immune thrombocytopenia (ITP)]] in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Code names:''' E-5501, YM-477, AKR-501 | |
| + | *'''Brand name:''' Doptelet | ||
| − | [[Category: | + | [[Category:Drugs]] |
| + | [[Category:Oral medications]] | ||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
| − | [[Category:Immune | + | [[Category:Immune thrombocytopenia medications]] |
| + | [[Category:Thrombocytopenia in liver disease medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2018]] | ||
| + | [[Category:EMA approved in 2019]] | ||
Latest revision as of 13:11, 8 September 2023
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is established
History of changes in FDA indication
- 2018-05-21: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
History of changes in EMA indication
- 2019-06-20: Initial authorization as Doptelet
- Uncertain date: Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
- Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Also known as
- Code names: E-5501, YM-477, AKR-501
- Brand name: Doptelet